Literature DB >> 19961546

In vitro antimicrobial activity and mechanism of action of novel carbohydrate fatty acid derivatives against Staphylococcus aureus and MRSA.

P Nobmann1, P Bourke, J Dunne, G Henehan.   

Abstract

AIMS: This study investigates the antimicrobial activity and mode of action of novel carbohydrate fatty acid (CFA) derivatives against Staphylococcus aureus and methicillin-resistant Staph. aureus (MRSA). METHODS AND
RESULTS: Minimum inhibitory concentrations (MICs) and the effect of CFA derivatives on lag phase were determined using a broth microdilution method. Lauric acid carbohydrate esters and corresponding ether analogues showed the greatest antimicrobial activity with MIC values between 0.04 and 0.16 mmol l(-1). Leakage studies at 260 nm following exposure to CFA derivatives at 4x MIC showed a significant increase in membrane permeability for all compounds, after c. 15 min exposure except for the lauric beta ether CFA derivative. Further assessment using both BacLight and luminescence ATP assays confirmed that an increase in membrane permeability and reduced metabolic activity was associated with CFA treatment.
CONCLUSIONS: All strains were significantly inhibited by the novel compounds studied, and efficacy was related to specific structural features. Cell-membrane permeabilization was associated with CFA treatment and may account for at least a component of the mode of action of these compounds. SIGNIFICANCE AND IMPACT OF THE STUDY: This study reports the antimicrobial action of CFA compounds against a range of Staph. aureus and MRSA strains, and provides insights into their mode of action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961546     DOI: 10.1111/j.1365-2672.2009.04622.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  7 in total

1.  Hydrophilic and lipophilic characteristics of non-fatty acid moieties: significant factors affecting antibacterial activity of lauric acid esters.

Authors:  Kyung-Min Park; Seon Joo Lee; Hyunjong Yu; Jun-Young Park; Ho-Sup Jung; Keesung Kim; Chang Joo Lee; Pahn-Shick Chang
Journal:  Food Sci Biotechnol       Date:  2018-03-15       Impact factor: 2.391

2.  Novel benzyl phenyl sulfide derivatives as antibacterial agents against methicillin-resistant Staphylococcus aureus.

Authors:  Kuo Lu; Qi Chen; Xiao-Fang Xu; Ying Meng; Jing Lin; Wei-Min Chen
Journal:  J Antibiot (Tokyo)       Date:  2019-11-14       Impact factor: 2.649

3.  Exposure to the proton scavenger glycine under alkaline conditions induces Escherichia coli viability loss.

Authors:  Donna Vanhauteghem; Geert Paul Jules Janssens; Angelo Lauwaerts; Stanislas Sys; Filip Boyen; Eric Cox; Evelyne Meyer
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

4.  Sensitization of Staphylococcus aureus to methicillin and other antibiotics in vitro and in vivo in the presence of HAMLET.

Authors:  Laura R Marks; Emily A Clementi; Anders P Hakansson
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

5.  Understanding the antimicrobial activity of selected disinfectants against methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Ebrahim Aboualizadeh; Violet V Bumah; Daniela S Masson-Meyers; Janis T Eells; Carol J Hirschmugl; Chukuka S Enwemeka
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

6.  New Benzimidazole-1,2,4-Triazole Hybrid Compounds: Synthesis, Anticandidal Activity and Cytotoxicity Evaluation.

Authors:  Hülya Karaca Gençer; Ulviye Acar Çevik; Serkan Levent; Begüm Nurpelin Sağlık; Büşra Korkut; Yusuf Özkay; Sinem Ilgın; Yusuf Öztürk
Journal:  Molecules       Date:  2017-03-27       Impact factor: 4.411

7.  Lauric Acid Is an Inhibitor of Clostridium difficile Growth in Vitro and Reduces Inflammation in a Mouse Infection Model.

Authors:  Hsiao-Ting Yang; Jenn-Wei Chen; Jagat Rathod; Yu-Zhen Jiang; Pei-Jane Tsai; Yuan-Pin Hung; Wen-Chien Ko; Daniel Paredes-Sabja; I-Hsiu Huang
Journal:  Front Microbiol       Date:  2018-01-17       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.